Sign in
Taking people in SwitzerlandPhase 1/2

Testing SX-682 with apalutamide in men with advanced prostate cancer

Tests SX-682 combined with apalutamide in men with metastatic castration-resistant prostate cancer.

Key facts

Who runs it
Institute of Cancer Research, United Kingdom
Where
Bellinzona, SwitzerlandSee the siteAlso in 1 other country, 3 sites
Trial code
Registry title
Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
Status
Recruiting
Phase
Phase 1/2
People taking part
78 people, planned
Started
28 Apr 2025
Expected to end
Oct 2029
Type of study
Interventional, 2 groups
Treatments tested
  • SX-682
  • Apalutamide
Record updated
8 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men with prostate cancer that has spread and no longer responds to hormone-lowering treatment. They must have already stopped responding to one next-generation antiandrogen drug.

Age
18 years or older
Sex
Men only
Disease stage
Metastatic castration-resistant prostate cancer (adenocarcinoma) that is getting worse by scans and/or PSA. PSA of 10 ng/ml or more, and testosterone under 50 ng/dL while on androgen deprivation.
Earlier treatment
Must have stopped responding to one next-generation antiandrogen (enzalutamide, apalutamide or darolutamide, at least 12 weeks). Must have had castration by surgery and/or ongoing LHRH agonist treatment. People who had abiraterone but no AR antagonist get an apalutamide lead-in first.

Main reasons for not taking part

  • Chemotherapy, surgery or other anti-cancer therapy in the last 4 weeks
  • History of seizures or brain metastases
  • Significant heart problems, such as QTcF over 470 msec or a heart attack in the last 6 months
  • Significant liver disease, or another cancer within 5 years (except treated basal cell carcinoma)
  • Taking prohibited medicines such as warfarin, lithium or certain antipsychotics and antidepressants

The registry criteria, word for word

Show all 37 criteriaShow less

Who can take part

  • Written informed consent and be capable of cooperating with treatment
  • Age ≥ 18 years
  • Histologically or biochemically confirmed adenocarcinoma of the prostate and with tumour tissue accessible for research analysis for this trial. Patients who have no histological diagnosis must be willing to undergo a biopsy to prove prostate adenocarcinoma
  • Patients recruited to phase 1 dose escalation cohorts must have biopsiable disease and consent to mandatory pre- and post-treatment biopsies (baseline and on Cycle 2 Day 1)
  • Metastatic castration-resistant prostate cancer
  • All patients must have documented resistance to 1 prior next generation antiandrogen therapy (NAAT) defined as:; For phase 1 and phase 2 Cohorts:; Patients who have progressed after either enzalutamide, Apalutamide or darolutamide (having received a minimum of 12-weeks of enzalutamide, Apalutamide or darolutamide) will enter phase 1 or phase 2 cohorts directly. Patients that have previously received abiraterone but not an AR antagonist should receive a lead-in with Apalutamide on trial and receive the combination on progression through the lead-in
  • Documented prostate cancer progression as assessed by the investigator with RECIST v1.1 and PCWG3 criteria (Section 3.5) with at least two of the following criteria:; Progression of soft tissue/visceral disease by RECIST v1.1 and/or,; Progression of bone disease by PCWG3 bone scan criteria and/or,; Progression of PSA by PCWG3 PSA criteria
  • PSA ≥ 10ng/ml
  • Received prior castration by orchiectomy and/or ongoing luteinizing hormone releasing hormone agonist treatment
  • Ongoing androgen deprivation with serum testosterone < 50 ng/dL (< 1.7 nM)
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤2
  • Documented willingness to use an effective means of contraception while participating in the study and for 6 months post last treatment dose
  • Able to swallow the study drug
  • All efforts should be made to discontinue steroid usage but up-to 5mg BD prednisolone (or equivalent) will be allowed
  • Haematological and biochemical indices within the ranges shown below. These measurements must be performed within one week (Day -7 to Day 1) before the patient goes on trial; Haemoglobin (Hb) ≥ 9.0 g/dL Absolute neutrophil count ≥ 1.5 x 109/L Platelet count ≥ 100 x 109/L WBC ≥ 3.0 x 109/L Calculated creatinine clearance ≥ 50 mL/min (uncorrected value) Serum bilirubin ≤ 1.5 x upper limit of normal (ULN) unless documented Gilbert's disease., in which case ≤ 3 x ULN is permissible Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x (ULN) unless raised due to known metastatic liver disease in which case ≤ 5 x ULN is permissible

Who cannot take part

  • Surgery, chemotherapy, or other anti-cancer therapy within 4 weeks prior to trial entry/randomisation into the study (with the exception of abiraterone, enzalutamide, Apalutamide or darolutamide). Any other therapy for prostate cancer, other than gonadotropin releasing hormone analogue therapy, such as progesterone, medroxyprogesterone, progestins or 5-alpha reductase inhibitors, must be discontinued at least 2 weeks before the first dose of the study drug
  • Participation in another interventional clinical trial of an IMP within 4 weeks prior to trial entry. Participation in trials of licensed medications is allowed provided the medication is not a prohibited concomitant medication
  • Prior limited field radiotherapy within 2 weeks and wide field radiotherapy within 4 weeks prior to trial entry
  • Any other finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect interpretation of the results or renders the patients at high risk from treatment complications, e.g., patients with a hypersensitivity to the active substance or any of the excipients
  • Unresolved significant toxicity from prior therapy (except alopecia and grade 1 peripheral neuropathy)
  • At high-risk because of non-malignant systemic disease including active infection and any serious concurrent illness
  • Is taking any of the following prohibited medications:; Aminophylline/theophylline; Atypical antipsychotics (eg, clozapine, olanzapine, risperidone, ziprasidone); Buproprion; Lithium; Meperidine and pethidine; Phenothiazine antipsychotics (eg, chlorpromazine, mesoridazine, thioridazine); Tricyclic and tetracyclic antidepressants (eg, amitriptyline, desipramine, doxepin, imipramine, maprotiline, mirtazapine; Warfarin or coumarin-like anticoagulants
  • History of previous non-infectious pneumonitis requiring steroid treatment, or active non-infectious pneumonitis
  • History of previous severe drug induced severe cutaneous reaction including but not limited to Steven-Johnson's syndrome/toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS)
  • History of seizures or other predisposing factors including, but not limited to, underlying brain injury, stroke, primary brain tumours, brain metastases and leptomeningeal disease, or alcoholism
  • Malabsorption syndrome or other condition that would interfere with enteral absorption
  • Clinically significant history of liver disease (Child-Pugh B or C, viral or other hepatitis, current alcohol abuse or cirrhosis)
  • Malignancy other than prostate cancer within 5 years of trial entry except for adequately treated basal cell carcinoma
  • Predominantly small cell or neuroendocrine differentiated (> 20% of cells) prostate cancer
  • Active or uncontrolled autoimmune disease requiring corticosteroid therapy
  • History of thromboembolic disease within 12 months of commencement of trial
  • Symptoms of COVID-19 and/or documented COVID-19 infection
  • Any of the following cardiac criteria:; QTcF interval > 470 msec; Clinically important abnormalities including rhythm, conduction, or electrocardiogram (ECG) changes (left bundle branch block, third degree heart block); Factors predisposing to QT prolongation including heart failure, hypokalaemia, congenital long QT syndrome, family history of prolonged QT syndrome, unexplained sudden death (under 40) and concomitant medications known to prolong QT interval; Coronary artery bypass, angioplasty, vascular stent, myocardial infarction, angina, congestive heart failure (NYHA ≥ grade 2) i or transient ischaemic attack) in the last 6 months (see appendix 4 for NYHA scale); Uncontrolled hypotension (systolic blood pressure < 90mmHg); Uncontrolled hypertension on optimal medical management
  • Clinical and/or biochemical evidence of hyperaldosteronism or hypopituitarism
  • Inability to comply with study and follow-up procedures
  • Immunocompromised patients
  • Any known intolerance to Apalutamide, SX-682, or to any constituents

This trial is currently available in Switzerland.

Also in 1 other country, 3 sites

  • Oncology Institute of Southern SwitzerlandBellinzona, SwitzerlandContact: Dr Ursula VoglTaking people

About the trial

What the trial wants to find out

ASpiRE will investigate the effect of the drug SX-682 in combination with Apalutamide in men suffering from metastatic castration-resistant prostate cancer (mCRPC).

The 2 groups in the trial

  • Phase I: Dose EscalationTreatment being tested

    Phase I will identify a biologically active and tolerable (safe) dose range of SX-682 in combination with Apalutamide in patients with metastatic castrate-resistant prostate cancer (mCRPC).

    Treatment: SX-682 and Apalutamide

  • Phase II: Dose ExpansionTreatment being tested

    Phase I will investigate the anti-tumour activity of tolerable doses of SX-682 in combination with Apalutamide in patients with metastatic castrate-resistant prostate cancer (mCRPC). Patients will be treated at dose levels deemed to be tolerable and biologically active, based on safety and efficacy data from Dose Escalation.

    Treatment: SX-682 and Apalutamide

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
ASpiRE: A Proof-of-mechanism and Proof-of-concept Clinical Trial Evaluating the Safety, Tolerability, Biological and Anti-tumour Activity of Apalutamide With Dual CXCR1 and CXCR2 Blockade by SX-682 for Men Suffering From Metastatic Castration-resistant Prostate Cancer (mCRPC)
Plain-language title
Testing SX-682 with apalutamide in men with advanced prostate cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
8 September 2026